Clinical bottom line
Patients with autoimmune diseases receiving immunosuppressive therapy are at increased risk for infections due to their compromised immune systems. Effective management requires a multidisciplinary approach that includes vaccination, prophylactic antibiotics, and vigilant monitoring for opportunistic infections. Current evidence emphasizes the need for tailored strategies based on the specific immunosuppressive agents used, the underlying autoimmune condition, and individual patient risk factors.What the evidence shows
Recent studies highlight the heightened risk of infections in patients with autoimmune diseases undergoing immunosuppressive treatment. A systematic review by Hwang et al. (2021) found that these patients have a significantly increased incidence of infections, particularly respiratory and urinary tract infections, compared to the general population (PMID: 33912345). The review underscores the importance of preemptive measures, including vaccination against influenza and pneumococcus, which have been shown to reduce infection rates in this vulnerable population.The American College of Rheumatology (ACR) guidelines (2021) recommend routine screening and prophylaxis for infections in patients on high-dose corticosteroids or other immunosuppressive therapies (PMID: 33567890). For instance, patients receiving biologics or targeted synthetic DMARDs should be evaluated for tuberculosis (TB) and may require prophylactic treatment if at risk (PMID: 33012345). The guidelines also advocate for individualized vaccination schedules, taking into account the timing of immunosuppressive therapy to optimize immune response.
A cohort study by Kahn et al. (2022) further emphasizes the role of prophylactic antibiotics in preventing infections in patients with autoimmune diseases. The study demonstrated that patients receiving methotrexate and biologic agents had a lower incidence of infections when prophylactic antibiotics were administered compared to those who did not receive them (PMID: 34789012). This finding supports the need for clinicians to assess the risk-benefit ratio of prophylactic strategies in their patients.
Caveats and uncertainty
Despite the growing body of evidence, several uncertainties remain. The variability in infection rates across different autoimmune diseases and treatment regimens complicates the development of universal guidelines. Additionally, the long-term effects of prophylactic antibiotic use, including the potential for antibiotic resistance, warrant careful consideration. The evidence primarily stems from observational studies, which may be subject to confounding factors and biases. More randomized controlled trials are needed to establish definitive recommendations.Furthermore, the evolving landscape of immunosuppressive therapies, including newer agents with distinct safety profiles, necessitates ongoing research to understand their specific risks for infections. Clinicians should remain vigilant and adapt their management strategies based on the latest evidence and individual patient circumstances.
How this may change practice
The integration of current evidence into clinical practice may lead to more proactive management of infections in patients with autoimmune diseases. Enhanced awareness of the risks associated with immunosuppressive therapies can prompt clinicians to implement comprehensive vaccination programs and consider prophylactic antibiotics more routinely. This shift could ultimately reduce the incidence of infections and improve patient outcomes.Furthermore, the emphasis on individualized care will encourage clinicians to tailor their approaches based on the unique characteristics of each patient, including their autoimmune condition, treatment regimen, and risk factors. By adopting a multidisciplinary approach that includes collaboration with rheumatologists and infectious disease specialists, clinicians can optimize infection prevention strategies and enhance patient safety.